Corbel et al. reported that in a mice model of bleomycin-induced lung fibrosis treatment with Batismastat, a synthetic MMP inhibitor, the levels of hydroxyproline, MMP-2, MMP-9 and histopathological findings of fibrosis were reduced [8]. The gene discussed is MMP9; the disease is pulmonary fibrosis.